Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
Panagiotis A. Konstantinopoulos, William T. Barry, Michael Birrer, Shannon N. Westin, Karen A. Cadoo, Geoffrey I. Shapiro, Erica L. Mayer, Roisin E. O'Cearbhaill, Robert L. Coleman, Bose Kochupurakkal, Christin Whalen, Jennifer Curtis, Sarah Farooq, Weixiu Luo, Julia Eismann, Mary K. Buss, Carol Aghajanian, Gordon B. Mills, Sangeetha Palakurthi, Paul KirschmeierJoyce Liu, Lewis C. Cantley, Scott H. Kaufmann, Elizabeth M. Swisher, Alan D. D'Andrea, Eric Winer, Gerburg M. Wulf, Ursula A. Matulonis
Dive into the research topics of 'Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial'. Together they form a unique fingerprint.